These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
294 related articles for article (PubMed ID: 35358493)
1. Small molecule CGRP receptor antagonists for the preventive treatment of migraine: A review. Dos Santos JBR; da Silva MRR Eur J Pharmacol; 2022 May; 922():174902. PubMed ID: 35358493 [TBL] [Abstract][Full Text] [Related]
2. Comparative efficacy, quality of life, safety, and tolerability of atogepant and rimegepant in migraine prevention: A matching-adjusted indirect comparison analysis. Tassorelli C; Onishchenko K; Halker Singh RB; Duan M; Dupont-Benjamin L; Hemstock M; Voller C; McAllister P; Nahas SJ; Gandhi P; Ailani J Cephalalgia; 2024 Feb; 44(2):3331024241235156. PubMed ID: 38410850 [TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness Evaluation of Oral CGRP Antagonists, Atogepant and Rimegepant, for the Preventative Treatment of Episodic Migraine: Results from a US Societal Perspective Model. Thaliffdeen R; Yu A; Rascati K Clin Drug Investig; 2024 Mar; 44(3):209-217. PubMed ID: 38381352 [TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability of atogepant for the preventive treatment of migraine: a post hoc analysis of pooled data from four clinical trials. Rizzoli P; Marmura MJ; Robblee J; McVige J; Sacco S; Nahas SJ; Ailani J; De Abreu Ferreira R; Ma J; Smith JH; Dabruzzo B; Ashina M J Headache Pain; 2024 Mar; 25(1):35. PubMed ID: 38462625 [TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial. Tassorelli C; Nagy K; Pozo-Rosich P; Lanteri-Minet M; Sacco S; Nežádal T; Guo H; De Abreu Ferreira R; Forero G; Trugman JM Lancet Neurol; 2024 Apr; 23(4):382-392. PubMed ID: 38364831 [TBL] [Abstract][Full Text] [Related]
11. Atogepant for Migraine Prevention: A Systematic Review of Efficacy and Safety. Singh A; Balasundaram MK Clin Drug Investig; 2022 Apr; 42(4):301-308. PubMed ID: 35230651 [TBL] [Abstract][Full Text] [Related]
12. Gepants - a long way to cure: a narrative review. Altamura C; Brunelli N; Marcosano M; Fofi L; Vernieri F Neurol Sci; 2022 Sep; 43(9):5697-5708. PubMed ID: 35650458 [TBL] [Abstract][Full Text] [Related]
13. Atogepant: First Approval. Deeks ED Drugs; 2022 Jan; 82(1):65-70. PubMed ID: 34813050 [TBL] [Abstract][Full Text] [Related]
14. Atogepant: an emerging treatment for migraine. Rustichelli C; Avallone R; Ferrari A Expert Opin Pharmacother; 2022 Apr; 23(6):653-662. PubMed ID: 35319319 [TBL] [Abstract][Full Text] [Related]
15. Update of Gepants in the Treatment of Chronic Migraine. Cho S; Kim BK Curr Pain Headache Rep; 2023 Oct; 27(10):561-569. PubMed ID: 37656319 [TBL] [Abstract][Full Text] [Related]
16. The pharmacotherapeutic management of episodic and chronic migraine with gepants. Tajti J; Szok D; Csáti A; Vécsei L Expert Opin Pharmacother; 2023 Jun; 24(8):947-958. PubMed ID: 37038933 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of atogepant, a small molecule CGRP receptor antagonist, for the preventive treatment of migraine: a systematic review and meta-analysis. Hou M; Luo X; He S; Yang X; Zhang Q; Jin M; Zhang P; Li Y; Bi X; Li J; Cheng C; Xue Q; Xing H; Liu Y J Headache Pain; 2024 Jul; 25(1):116. PubMed ID: 39030528 [TBL] [Abstract][Full Text] [Related]
18. Sustained response to atogepant in episodic migraine: post hoc analyses of a 12-week randomized trial and a 52-week long-term safety trial. Lipton RB; Nahas SJ; Pozo-Rosich P; Bilchik T; McAllister P; Finnegan M; Liu Y; Chalermpalanupap N; Dabruzzo B; Dodick DW J Headache Pain; 2024 May; 25(1):83. PubMed ID: 38773375 [TBL] [Abstract][Full Text] [Related]
19. Atogepant: Mechanism of action, clinical and translational science. Boinpally R; Shebley M; Trugman JM Clin Transl Sci; 2024 Jan; 17(1):e13707. PubMed ID: 38266063 [TBL] [Abstract][Full Text] [Related]
20. Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial. Schwedt TJ; Lipton RB; Ailani J; Silberstein SD; Tassorelli C; Guo H; Lu K; Dabruzzo B; Miceli R; Severt L; Finnegan M; Trugman JM Cephalalgia; 2022 Jan; 42(1):3-11. PubMed ID: 34521260 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]